“We expect the fourth quarter to be similar, and we're going to try and keep that momentum going here in the new year as well.”

In context

“oritized. So, the orders were negative to repeat, but not unexpectedly and to be seen in the context of a market that is now readjusting. Matt McGrew: And Derik, you had asked about the non-COVID as well. So if you think about the book-to-bill there in the quarter, it was essentially 1.0. Derik De Bruin: I'm sorry, what? Matt McGrew: Essentially, 1, 1.0. Derik De Bruin: Okay. Got it. And do you still -- and just one final question. Do you still expect to take significant price across the portfolio next year? Rainer Blair: We continue to think about price as a lever for us. And we think that lever is available to us next year as well. We have taken the necessary steps to do that. We're over 400 basis points here in the quarter. That's up from 300 basis points in the first half of the year. We expect the fourth quarter to be similar, and we're going to try and keep that momentum going here in the new year as well. Matt McGrew: And that commentary is overall, Derik, but I don't think that, that would be any different for Bioprocessing numbers. Operator: We'll take our next question from Scott Davis with Melius Research. Scott Davis: Go back a little bit to Cepheid. Are there costs -- I would imagine that cost was not a main focus when you were supplying just extreme demand for quite the last couple of years. But are there costs or is there a playbook where cost can come out of the business and to give you a little bit of a tailwind on the margin side while growth kind of stabilizes? Rainer Blair: So we have, as you suggested, invested significantly in order to drive -- to be able to supply the demand here during the pandemic and watch very carefully where our capacity needs to be, one, to, of course”